Journal
NANO RESEARCH
Volume 15, Issue 5, Pages 4191-4200Publisher
TSINGHUA UNIV PRESS
DOI: 10.1007/s12274-021-4012-9
Keywords
severe acute respiratory syndrome coronavirus 2 (SASR-CoV-2); inhalation; nanovaccine; chitosan
Categories
Funding
- National Key R&D Program of China [2019YFA0904200, 2018YFA0507600]
- Tsinghua University Spring Breeze Fund [2020Z99CFY042]
- National Natural Science Foundation of China [92053108]
Ask authors/readers for more resources
This study presents an inhalable nanovaccine consisting of chitosan and SARS-CoV-2 spike protein, which induces a strong immune response and enhances local mucosal immunity in the lungs, potentially protecting against the virus.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with several antigenic variants, has grown into a global challenge, and the rapid establishment of an immune barrier is crucial to achieving long-term control of the virus. This has led to a great demand for easy preparation and scalable vaccines, especially in low-income countries. Here, we present an inhalable nanovaccine comprising chitosan and SARS-CoV-2 spike protein. The chitosan-mediated nanovaccine enabled a strong spike-specific antibody immune response and augmented local mucosal immunity in bronchoalveolar lavage and lungs, which might be capable of protecting the host from infection without systemic toxicity. In addition, the enhanced adaptive immunity stimulated by chitosan showed potential protection against SARS-CoV-2. Furthermore, inhalation of the nanovaccine induced a comparable antibody response compared to intramuscular injection. This inhalable nanovaccine against SARS-CoV-2 offers a convenient and compliant strategy to reduce the use of needles and the need for medical staff.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available